Update on Phase III GY004 trial for cediranib
12 March 2020 07:00 GMT Update on Phase III GY004 trial for cediranib added toLynparza in platinum-sensitive relapsed ovarian cancer The trial did not meet the primary endpoint of progression-free survival vs. platinum-based chemotherapy AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced high-level results from the Phase III GY004 trial, led by NRG Oncology and sponsored by the US National Cancer Institute (NCI), that examined primarily the efficacy and safety of the potential new medicine